S. Uslu Et Al. , "The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry," Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP) , Illinois, United States Of America, 2018
Uslu, S. Et Al. 2018. The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry. Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP) , (Illinois, United States Of America).
Uslu, S., CAN, G., ŞENEL, A. S., DALKILIÇ, H. E., Inanc, N., Akars, S., ... Kocaer, S. B.(2018). The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry . Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP), Illinois, United States Of America
Uslu, Sadettin Et Al. "The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry," Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP), Illinois, United States Of America, 2018
Uslu, Sadettin Et Al. "The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry." Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP) , Illinois, United States Of America, 2018
Uslu, S. Et Al. (2018) . "The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry." Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Sadettin Uslu Et Al. }, title={The Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry}, congress name={Annual Meeting of the American-College-of-Rheumatology (ACR) and Association-for-Rheumatology-Health-Professionals (ARHP)}, city={Illinois}, country={United States Of America}, year={2018}}